Status: Not yet recruiting
A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3
The purpose of this study is to to evaluate the safety, tolerability, immunogenicity, and efficacy of RG002 Injection in subjects with HPV16/18 associated Cervical Intraepithelial Neoplasia Grade 2 or 3(CIN2/3).
Participants needed: 39
Trial details
Phase: Phase 1, Phase 2Age: 18-55Biological sex: FemaleType: InterventionalSponsor: RinuaGene Biotechnology Co., Ltd.Updated: Feb 22, 2024
Eligibility criteria
Written informed consent in accordance with study site guidelines. [+11]
Cervical adenocarcinoma in situ (AIS), or atypical endometrial or glandular cell... [+23]